On Friday, October 24, 2025, Biogen Inc. announced it had secured global rights to Vanqua Bio’s experimental oral C5aR1 antagonist, a preclinical immunology candidate, in a deal that could bring up to $1.06 billion in total payments. The agreement includes a $70 million upfront payment and up to $990 million in milestone and royalty payments.
The C5aR1 antagonist targets the complement component C5a receptor, a key driver of neutrophil‑mediated inflammation implicated in a range of autoimmune and inflammatory disorders. By adding this oral small‑molecule platform, Biogen expands its immunology pipeline beyond its existing antibody‑based assets such as felzartamab and litifilimab.
Biogen said it expects to file an Investigational New Drug application in 2027 if preclinical data remain supportive. The deal aligns with the company’s “Fit for Growth” strategy to diversify revenue sources and strengthen its position in high‑unmet‑need therapeutic areas.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.